Good news, Bensocatib Trials Continue for Bronchieactasis

Posted by harrynsc @harrynsc, May 28 5:32pm

Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.

@scoop @ rstel7272 @harrynsc
So, umm...let me point out this is a Stock Report, not a medical research paper. Can anyone point us to the underlying data - Phase 3 FDA research, double-blind study or retrospective evaluation?

REPLY

Check out Linda Esposito's (@becleartoday) post of May 28 re Clinical Trials - she is a trustworthy source! Fingers crossed this is the real deal.

REPLY
@becleartoday

Brensocatib--
Insmed said its experimental drug to treat a type of chronic lung disease helped significantly reduce respiratory symptoms such as chronic cough in a late-stage study.
The drug candidate, brensocatib, is being developed to treat patients with non-cystic fibrosis bronchiectasis, a chronic lung condition where the walls of the airways are widened due to inflammation and infection.
The company said it plans to file a marketing application for brensocatib with the U.S. Food and Drug Administration in the fourth quarter of this year, and it expects to launch the drug in mid-2025.

Jump to this post

Hello @becleartoday - I merged your discussion with @harrynsc's discussion on the same topic - https://connect.mayoclinic.org/discussion/good-news-for-bronchiectasis/ so all of the members talking about this study could be in one place.

Like @sueinmn mentioned, the article linked in this discussion is a stock report. Have you been able to track down the study data link that you are referring to? I found one article, but it is from 2020, https://www.nejm.org/doi/full/10.1056/NEJMoa2021713.

REPLY

What I'd want to know is how many participants were in the study and over what period of time.

REPLY
@JustinMcClanahan

Hello @becleartoday - I merged your discussion with @harrynsc's discussion on the same topic - https://connect.mayoclinic.org/discussion/good-news-for-bronchiectasis/ so all of the members talking about this study could be in one place.

Like @sueinmn mentioned, the article linked in this discussion is a stock report. Have you been able to track down the study data link that you are referring to? I found one article, but it is from 2020, https://www.nejm.org/doi/full/10.1056/NEJMoa2021713.

Jump to this post

The news just came out yesterday, so there aren’t medical journal articles on this top line data at this point in time.

I created this general discussion of ongoing active clinical trials at Colleen Young’s suggestion. But if you wish to move this to a previous discussion on brensocatib that makes sense as well.

You can read about the clinical trial by clicking on the link below. Also, if you Google “Aspen” and “brensocatib” you will find earlier articles from clinical and scientific journals.
https://classic.clinicaltrials.gov/ct2/show/NCT04594369
Many of us have been waiting for this information ever since the trial completed its in enrollment in March 2023 of 1700 participants. Yesterday‘s news was tremendously significant for those of us with bronchiectasis who have frequent exacerbations. Even at the lower dose, there was approximately a 20% reduction in exacerbations. If approved by the FDA, this will be the first drug approved specifically for BE.

REPLY

The Arina-1 seems a lot more promising and benign in terms of side-effects. But still I am happy BE is finally getting attention from drug developers.

REPLY

Yes!! BE is getting lots of attention. Brensocatib is considered to have a safe profile. On a recent call with industry and clinicians there was consensus that their drug would probably not need to be reviewed by the FDA adverse event committee.

Also, it’s meant for people who have frequent exacerbations.

Arina-1 Will perhaps be appropriate for the general bronchiectasis population.

REPLY
@becleartoday

Yes!! BE is getting lots of attention. Brensocatib is considered to have a safe profile. On a recent call with industry and clinicians there was consensus that their drug would probably not need to be reviewed by the FDA adverse event committee.

Also, it’s meant for people who have frequent exacerbations.

Arina-1 Will perhaps be appropriate for the general bronchiectasis population.

Jump to this post

Any of these available??

REPLY
Please sign in or register to post a reply.